fda pulls tirzepatide What is the latest update on the Compounded ban FDA says shortage of GLP-1

it would not establish that a finished compounded peptide is safe, effective, standardized, or FDA-approved for a particular condition

Additional safety considerations include risk of dehydration and acute kidney injury, potential worsening of diabetic retinopathy with rapid glucose improvement (particularly with semaglutide), and hypoglycemia risk when combined with insulin or sulfonylureas

Point-of-care/clinic testing: vaginal pH, microscopy or NAATs where appropriate

Preserving Muscle Mass: Protein Targets and Strength Work Weight loss on GLP-1 medications can move quickly particularly in the first several months